ASXL1 and myeloid neoplasm: These frequencies are consistent with those reported in myeloid malignancies; Schnittger et al. found that p.G646Wfs*12 accounted for 69 out of 128 ASXL1 mutations (53.9%), followed by p.E635Rfs*15 (18/128, 14.2%) [36].